Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Current guidelines recommend intravenous antibiotic therapy for at least 4 wk in patients with high-risk
Staphylococcus aureus
bacteremia (SAB), because of the risk for metastatic infection. We evaluated the safety of a shorter duration of treatment in patients with high-risk SAB without signs of metastatic infection at presentation, using standard
18
F-FDG PET/CT and echocardiography.
Methods:
Retrospective analyses were performed of patients with SAB admitted between 2013 and 2017 in 2 medical centers. Patients with risk factors for complicated bacteremia (community acquisition, persistently positive blood cultures, >72 h of fever, or foreign body materials present), a normal echocardiography result, and
18
F-FDG PET/CT without signs of metastatic infection were included (cases) and compared with patients with uncomplicated bacteremia (absence of any of the risk factors and no known
metastatic disease
, controls). Primary outcomes were 3-mo SAB-specific mortality rate and recurrent infection. The secondary outcome was overall mortality.
Results:
We included 36 cases and 40 controls. Both groups had a similar treatment duration (15.9 vs. 15.4 d). No deaths occurred as a consequence of SAB in the cases, compared with 1 in the control group. One relapse occurred in the case group and 2 in the control group. Overall mortality did not differ between the groups (19.4% vs. 15.0%,
P
= 0.64).
Conclusion:
This study suggests that intravenous treatment for 2 wk in high-risk patients with SAB without
endocarditis
and absence of metastatic infection on
18
F-FDG PET/CT is safe. A diagnostic-driven approach using
18
F-FDG PET/CT to determine treatment duration in high-risk SAB seems feasible and allows tailoring treatment to individual patients.
...
PMID:
18
F-FDG PET/CT-Guided Treatment Duration in Patients with High-Risk
Staphylococcus Aureus
Bacteremia: A Proof of Principle. 3055 2
Central venous catheter-associated bacteraemia caused by Nocardia species is very rare; the diagnosis of nocardiosis in patients with cancer is challenging because its clinical presentation is varied, sometimes mimicking
metastases
, and the high index of clinical suspicion is required for prompt institution of therapy. Herein, we report a case of nocardial sepsis with native aortic valve
endocarditis
in a patient with breast cancer in whom multidisciplinary team involvement and prompt initiation of therapy have led to successful outcome.
...
PMID:Nocardial endocarditis in native aortic valve with nocardial sepsis in a case of breast cancer. 3130 May 97
Staphylococcus aureus
bacteremia (SAB) is a serious cause of bloodstream infection associated with significant morbidity and mortality. Complications include deep-seated foci of infection including infective
endocarditis
, device-associated infection, osteoarticular
metastases
, pleuropulmonary involvement, and recurrent infection. With the 30-day all-cause mortality being around 20%, a collaborative effort of early Infectious Diseases (ID) consultation and Antimicrobial Stewardship Program (ASP) involvement will show improved SAB outcomes and therapy optimization.1.
...
PMID:
Staphylococcus aureus
Bacteremia: Contemporary Management. 3284 71
<< Previous
1
2
3
4
